Clearmind Medicine (CMND) announced the filing of an Israeli patent application for its combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, addressing depression. The patent application stems from Clearmind’s collaboration with Neurothera Labs, a subsidiary of SciSparc (SPRC). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280M people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Atai Beckley, Cybin report quarterly earnings
- Clearmind Medicine receives final approval to expand Phase 1/2a AUD trial
- Clearmind announces notice of publication of patent for MEAI in China
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Psychedelic: Compass Pathways, GH Research report Q3 earnings